Review: Corneal endothelial cell derivation methods from ES/iPS cells

被引：30

作者：

Hatou S. ^{[1
]}

Shimmura S. ^{[1
]}

机构：

[1] Department of Ophthalmology, Keio University, School of Medicine, 35 Shinanomchi, Shinjuku-ku, Tokyo

来源：

Inflammation and Regeneration | / 39卷 / 1期

关键词：

Bone morphogenetic protein; Embryonic stem cells; Epithelial-mesenchymal transition; Induced pluripotent stem cells; Neural crest cells; Transforming growth factor beta; Wnt;

D O I：

10.1186/s41232-019-0108-y

中图分类号：

学科分类号：

摘要：

Globally, approximately 12.7 million people are awaiting a transplantation, while only 185,000 cases of corneal transplantation are performed in a year. Corneal endothelial dysfunction (bullous keratopathy) due to Fuchs' corneal endothelial dystrophy, or insults associated with intraocular surgeries, shared half of all indications for corneal transplantation. Regenerative therapy for corneal endothelium independent of eye bank eyes has great importance to solve the large supply-demand mismatching in corneal transplantation and reduce the number of worldwide corneal blindness. If corneal endothelial cells could be derived from ES or iPS cells, these stem cells would be the ideal cell source for cell therapy treatment of bullous keratopathy. Four representative corneal endothelial cell derivation methods were reviewed. Components in earlier methods included lens epithelial cell-conditioned medium or fetal bovine serum, but the methods have been improved and materials have been chemically more defined over the years. Conditioned medium or serum is replaced to recombinant proteins and small molecule compounds. These improvements enabled to open the corneal endothelial developmental mechanisms, in which epithelial-mesenchymal and mesenchymal-endothelial transition by TGF beta, BMP, and Wnt signaling have important roles. The protocols are gradually approaching clinical application; however, proof of efficacy and safety of the cells by adequate animal models are the challenges for the future. © 2019 The Author(s).

引用

共 19 条

[1] Gain P., Jullienne R., He Z., Aldossary M., Acquart S., Cognasse F., Et al., Global survey of corneal transplantation and eye banking, JAMA Ophthalmol, 134, 2, pp. 167-173, (2016)
[2] Dawson D.G., Ubels J.L., Edelhauser H.F., Cornea and Sclera, (2011)
[3] Nishida T., Saika S., Cornea and Sclera: Anatomy and Physiology, (2011)
[4] Kinoshita S., Koizumi N., Ueno M., Okumura N., Imai K., Tanaka H., Et al., Injection of cultured cells with a ROCK inhibitor for bullous keratopathy, N Engl J Med, 378, 11, pp. 995-1003, (2018)
[5] Zavala J., Lopez Jaime G.R., Rodriguez Barrientos C.A., Valdez-Garcia J., Corneal endothelium: Developmental strategies for regeneration, Eye (London, England), 27, 5, pp. 579-588, (2013)
[6] Joyce N.C., Harris D.L., Mello D.M., Mechanisms of mitotic inhibition in corneal endothelium: Contact inhibition and TGF-beta2, Invest Ophthalmol Vis Sci, 43, 7, pp. 2152-2159, (2002)
[7] Saika S., Saika S., Liu C.Y., Azhar M., Sanford L.P., Doetschman T., Et al., TGFbeta2 in corneal morphogenesis during mouse embryonic development, Dev Biol, 240, 2, pp. 419-432, (2001)
[8] Zacharias A.L., Gage P.J., Canonical Wnt/beta-catenin signaling is required for maintenance but not activation of Pitx2 expression in neural crest during eye development, Dev Dyn: An Official Publication of the American Association of Anatomists., 239, 12, pp. 3215-3225, (2010)
[9] Bennett J.L., Zeiler S.R., Jones K.R., Patterned expression of BDNF and NT-3 in the retina and anterior segment of the developing mammalian eye, Invest Ophthalmol Vis Sci, 40, 12, pp. 2996-3005, (1999)
[10] Collinson J.M., Quinn J.C., Hill R.E., West J.D., The roles of Pax6 in the cornea, retina, and olfactory epithelium of the developing mouse embryo, Dev Biol, 255, 2, pp. 303-312, (2003)

← 1 2 →